Mark Foley compensation by year
Revance Therapeutics Summary Compensation Table · all 5 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Salary | $189,764 | $650,000 | $660,000 | $673,200 | $720,000 |
| Bonus | $150,000 | $0 | $0 | $0 | $0 |
| Stock awards | $11,728,370 | $7,794,350 | $4,561,652 | $4,178,690 | $8,810,731 |
| Option awards | $5,112,573 | $0 | $1,141,226 | $1,099,525 | $0 |
| Non-equity incentive | $0 | $328,331 | $425,700 | $640,870 | $522,720 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $9,723 | $8,255 | $317,338 | $14,631 | $15,464 |
| Total | $17,190,430 | $8,780,936 | $7,105,916 | $6,606,916 | $10,068,915 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Revance Therapeutics, Inc. DEF 14A filed March 21, 2024, accession 0001479290-24-000071, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Revance Therapeutics, Inc. filed document, accession 0001479290-24-000071. Every figure is read from that document and cited to the page and table it appears in. Filed March 21, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 344,000 | $3,023,760 | — |
| PSU | 254,058 | $2,233,170 | — |
| RSU | 13,572 | $119,298 | — |
| Option | 77,624 | — | $13.08 |
| Option | 21,486 | — | $28.01 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Revance Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2023 proxy (filed March 21, 2024)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-02-06 | Disposition to the issuer | — | 84,686 | — | 0 |
| 2025-02-06 | Grant or award | — | 84,686 | $0.00 | 84,686 |
| 2025-02-06 | Disposition to the issuer | — | 27,933 | — | 0 |
| 2025-02-04 | U | — | 996,935 | $3.65 | 27,933 |
| 2025-02-04 | U | — | 110,913 | $3.65 | 0 |
| 2025-02-03 | Grant or award | — | 27,933 | $0.00 | 1,024,868 |
| 2024-12-31 | Grant or award | — | 1,000 | $2.18 | 996,935 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Revance Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Mark Foley · this page | Chief Executive Officer | $10,068,915 |
| Dustin Sjuts | President | $4,581,630 |
| Tobin Schilke | Chief Financial Officer | $3,974,145 |
| Dwight Moxie | Chief Legal Officer | $3,528,145 |
Board service
Revance Therapeutics board · FY2022–FY2023How this board is paid
Company policy: Revance Therapeutics pays directors a $50,000 cash retainer and $225,000 in 50% RSAs / 50% Options. As stated in Revance Therapeutics's FY2023 proxy.
The full Revance Therapeutics compensation record
free company briefThis page is one person within Revance Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Revance Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Revance Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.